Shricon Industries Limited is a Rajasthan-based public limited company currently undergoing a strategic transformation. Historically rooted in **civil construction** and **real estate development** for the **mid and lower-income segments**, the company is aggressively diversifying into the **pharmaceutical wholesale** and **healthcare e-commerce** sectors. This transition aims to leverage the company’s existing digital infrastructure and family legacy in Rajasthan to capture growth in the high-margin wellness market. --- ### **Strategic Pivot: Pharmaceutical & Healthcare Expansion** The company has identified **Pharmaceuticals, Nutraceuticals, and Ayurveda** as its primary future growth engines. As of **mid-2025**, Shricon has transitioned from the planning phase to the operational readiness phase in this segment. * **Regulatory Milestones:** On **July 15, 2025**, the company secured critical wholesale drug licenses from the **Food Safety and Drug Control Commissionerate, Rajasthan**: * **Form 20B:** License for drugs other than those specified in **Schedules C, C(1), and X**. * **Form 21B:** License for drugs specified in **Schedules C and C(1)** (excluding Schedule X). * **Infrastructure & Compliance:** * Operations are headquartered in a **280.00 Sq. Feet** facility in **Kota, Rajasthan**. * The facility is equipped with cold chain storage capabilities maintaining temperatures between **2°C to 8°C**. * Licenses are valid perpetually, contingent upon a retention fee paid every **5 years**. * **E-commerce Integration:** Shricon intends to utilize its existing e-commerce platform to trade healthcare products, creating a hybrid physical-digital distribution model. --- ### **Core Legacy Verticals: Real Estate & Civil Work** Despite the pivot to healthcare, Shricon maintains its presence in the Rajasthan real estate market, focusing on affordable housing and consultancy. * **Target Demographic:** Focus remains on providing housing solutions for **mid and lower-income groups**, capitalizing on post-pandemic demand for larger carpet areas. * **Operational Strategy:** The company employs a systematic approach to acquiring **large land tracts** at reasonable rates to mitigate high acquisition costs. * **Asset Monetization:** In **May 2023**, the company demonstrated a commitment to debt reduction by disinvesting a property in **Bundi, Rajasthan** for **Rs. 2,50,00,000**, utilizing the proceeds to settle creditor obligations. --- ### **Financial Structure & Capital Management** Shricon has significantly deleveraged its balance sheet over the recent fiscal periods, improving its equity-to-debt ratio and overall financial stability. **Capital Structure Overview** | Particulars (₹ in Lacs) | As at March 31, 2023 | As at March 31, 2022 | | :--- | :--- | :--- | | **Gross Borrowings** | **101.81** | **377.09** | | **Cash & Cash Equivalents** | **1.68** | **1.94** | | **Net Debt** | **100.13** | **375.15** | | **Equity Share Capital** | **124.00** | **124.00** | | **Other Equity** | **221.82** | **100.87** | | **Total Equity (Capital)** | **345.82** | **224.87** | **Liquidity & Debt Maturity (as of March 31, 2023)** * **Interest-bearing Borrowings:** **₹101.81 Lacs** with a maturity profile of **2-4 years**. * **Current Liabilities:** **₹0.59 Lacs** due within one year or on demand. * **Credit Risk Management:** The company maintains a **low credit risk** profile by evaluating trade receivables based on age, customer track records, and collateral quality. --- ### **Governance, Leadership & Related Party Framework** The company has restructured its leadership to align with its new pharmaceutical and e-commerce objectives. * **Key Appointments:** * **Mr. Sheetal Jain:** Appointed as **Executive Director** for a 5-year term (**2025–2030**). * **Mr. Praveen Chandna:** Appointed as **Additional and Non-Executive Independent Director** (July 2025). * **Mr. Om Prakash Maheshwari:** Director and key stakeholder. * **Strategic Partnerships:** The company engages in significant transactions with **Career Point Edutech Limited**. For the **2023-24** period, the board sought approval for transactions (Sales/Purchase) up to a maximum value of **₹5 Crores** per annum, conducted on an **Arm’s Length Basis**. * **Auditor Status:** Following the resignation of **Kalani & Co.** in 2023 (due to fee adequacy issues), the company appointed **M/s R. S. Dani & Co.** as Statutory Auditors until **2028**. --- ### **Risk Matrix & Mitigation Profiles** | Risk Category | Impact Detail | Mitigation Strategy | | :--- | :--- | :--- | | **Market Cyclicality** | Real estate is non-moveable and harder to liquefy than commodities like gold. | Diversification into high-liquidity **Pharmaceutical** wholesale trade. | | **Interest Rate Risk** | Fluctuations affecting cash flows and borrowing costs. | Parking surplus in **Fixed Deposits**; bargaining for competitive bank rates. | | **Foreign Exchange** | Exposure from potential international sourcing. | Managed via **forward contracts** and natural hedging (local currency purchasing). | | **Operational Risk** | Rising land costs and regulatory approval fees. | Focus on **Joint Ventures** to fund large-scale projects and reduce capital outlay. | | **Liquidity Risk** | Meeting obligations as they fall due. | Maintaining **committed credit lines** and rolling liquidity forecasts. | --- ### **Operational Infrastructure & Compliance** * **Registered Office:** 112B, First Floor, Shakti Nagar, **Kota, Rajasthan-324009**. * **Banking Partners:** **AU Small Finance Bank** and **ICICI Bank Ltd**. * **Human Capital:** As of **June 2024**, the company reported **no employees** eligible for Defined Contribution/Benefit Plans; long-term benefits are restricted to **Leave Encashment** settled annually. * **Regulatory Adherence:** The company is currently stabilizing its secretarial department to ensure full compliance with **SEBI (LODR) Regulations** following the resignation of the Company Secretary in **November 2024**.